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2450Our study has the unique peculiarity in being speciﬁcally
designed to investigate the effect of percutaneous PFO closure upon
post-procedural atrial arrhythmias. All patients included in the
study underwent 1 to 3 months before closure to rhythm moni-
toring by using traditional 24-/48-h Holter-ECG recording or
external loop recorder monitoring (one-third). ECG recording
has been repeated 3 to 6 months after transcatheter PFO closure,
a time interval considered optimal for the anatomical stabiliza-
tion of the device. The main ﬁnding of our study is that percuta-
neous PFO closure is not per se an inductor for post-procedural
atrial arrhythmias; indeed, the only predictor of post-procedural
arrhythmias appear to be the presence of arrhythmias before PFO
closure. Interestingly, the majority of patients with post-procedural
arrhythmias had the same arrhythmias before PFO closure thus
suggesting an intrinsic increased susceptibility to develop rhythm
disturbances (4). Indeed, at multivariate analysis we could not
identify any predictors of post-procedural arrhythmias except pre-
closure arrhythmias. In particular, residual RLS, device type and
size, atrial and PFO anatomical features were not predictive of post-
procedural arrhythmias. This ﬁnding suggests that the device-
related atrial mechanical stretch per se does not increase electrical
vulnerability in nonsusceptible patients.
An interesting ancillary ﬁnding of this study, albeit non con-
clusive for the lack of a control group, is that the prevalence of
atrial arrhythmias, including atrial ﬁbrillation, in patients with
PFO is unexpectedly higher than that estimated in the general
population (5). This evidence suggests that, at least in a proportion
of patients with PFO, asymptomatic unrecognized arrhythmias
might play a pathogenetic role in systemic embolism. An obvious
ﬂaw of the present study is the technical limitation of the recor-
ding systems used that probably underestimated the true prevalence
of arrhythmias. Furthermore, our study lacks a control group so no
deﬁnite conclusions can be drawn regarding the prevalence of SV
arrhythmias in patients with PFO.
In conclusion, PFO closure does not appear to be per se an
inductor of post-procedural arrhythmias. The high prevalence of
arrhythmias detected before and after PFO closure may be related
to an increased atrial electrical vulnerability in patients with atrial
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Heart J 2012;33:2719–47.Letters to the EditorEnalapril/Carvedilol for Prevention
of Chemotherapy-Induced
Heart Failure
An End to the ProblemI read with great interest the article by Bosch et al. (1) looking at
enalapril and carvedilol for prevention of chemotherapy-induced
left ventricular systolic dysfunction (LVSD).
Clinical endpoints of the study raise a few important questions.
1. Cardinale et al. (2) randomized patients with elevated
troponin levels after high-dose chemotherapy into enalapril
and placebo treatment groups and showed that enalapril
prevented a>10% drop in LV ejection fraction (LVEF) when
compared with placebo (0% vs. 43%; p < 0.001). The
current study contradicts the Cardinale et al. (2) work because
they did not ﬁnd any interaction between the effects of ena-
lapril/carvedilol on EF and troponin elevation (p ¼ 0.59).
2. Compared with controls, patients in the intervention group
had a lower incidence of the combined event of death, heart
failure, and ﬁnal LVEF <45% (6.7% vs. 24.4%; p ¼ 0.02).
Looking closely, sepsis was a major confounding factor in
interpretation of these results because it was the major driver
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2451of mortality in the trial (5 in the control group vs. 2 in the
intervention group) and a major contributor to reducing the
LVEF (patients who survived a septic episode experienced
a mean decrease in LVEF of 4.6  9 points, compared with
a decrease of 0.6  6 points in patients without sepsis
(p ¼ 0.04). Additionally, enalapril and carvedilol did not
show any statistically signiﬁcant difference in reducing the
incidence of heart failure or preventing the reduction in
LVEF >10% (p ¼ 0.22). This leaves us with 2 possibilities:
either 1) enalapril/carvedilol was not effective in preventing
LVSD in patients undergoing high-dose chemotherapy; or
2) enalapril/carvedilol might be effective in preventing heart
failure in certain subgroups of patients (e.g., those with ele-
vated troponin levels after chemotherapy). Larger random-
ized controlled trials are needed to answer these questions.*Harsh Golwala, MD
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Preventing Chemotherapy-
Induced Left Ventricular
Systolic DysfunctionWe read with great interest the article by Bosch et al. (1). We
congratulate the authors for their work, which sheds new light on
the potential for preventing cardiotoxic effects of anticancer ther-
apies. However, there are a few aspects that, in our opinion, need
clariﬁcation.
First, carvedilol is not only a beta-blocker, but also an antioxi-
dant agent. It has been proven that such antioxidant effects of
carvedilol play a crucial role in protecting cardiomyocytes from the
cardiotoxic effect of anthracyclines (2), and therefore, this should be
taken into account when the results of the study by Bosch et al. (1)
are analyzed.
Second, we noted that 8 patients (18%) in the control group were
hypertensive. We would like to underline that hypertension has to
be treated in all patients undergoing chemotherapy, and mostimportantly, angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers and beta-blockers should be part of
the therapeutic regimen. It is recommended that patients switch
from other drug classes to these agents before the start of chemo-
therapy (3).
Third, we believe that in the setting of high-dose chemotherapy
in very frail patients, the greatest effort should be put forth to
prevent, not only cardiotoxicity, but also any condition that may
hamper the correct execution of the planned chemotherapy. The
study protocol by Bosch et al. (1) provided that enalapril and car-
vedilol had to be started simultaneously with dose titrations every
3 to 6 days. Even if the association between ACE inhibitors and
beta-blockers is highly recommended in heart failure, practice
guidelines suggest that ACE inhibitor therapy should be started
ﬁrst, quickly followed by beta-blocker therapy, and recommend
waiting 1 to 2 weeks before increasing doses (4). Bosch et al. (1)
reported that in their hands the ACE inhibitor and beta-blocker
combined therapy was safe and that only 6 patients stopped car-
vedilol, enalapril, or both. However, we believe that the protocol of
the OVERCOME (Prevention of Left Ventricular Dysfunction
With Enalapril and Carvedilol in Patients Submitted to Intensive
Chemotherapy for the Treatment of Malignant Hemopathies) trial
might be a “double-edged sword”: although the protocol reduced
the risk of cardiotoxicity, it also increased the risk that patients
could not receive the optimal chemotherapy regimen due to adverse
effects, such as severe and/or symptomatic hypotension, which may
inﬂuence both patient’s compliance and physician’s evaluation.
Accordingly, we believe that this approach should be tested in
a larger number of patients and should be taken into consideration
only when there is strong cooperation between oncologists and
cardiologists.
Fourth, Bosch et al. (1) found that the combined treatment
with enalapril and carvedilol did not prevent troponin elevation
and that troponin elevation was not predictive of left ventricular
dysfunction. This ﬁnding is very important because it is in sharp
contrast to many studies that have demonstrated that troponin is
a tool for early identiﬁcation, assessment, and monitoring of an-
ticancer drug–induced cardiac injury. These studies have inﬂu-
enced the development of the European Society for Medical
Oncology Clinical Practice Guidelines that suggest evaluating
troponin serum levels during high-dose chemotherapy for the
early identiﬁcation of patients at risk of developing cardiac dys-
function (5).*Paolo Spallarossa, MD
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